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Current, widely accepted guidelines for the management of HIV-associated cryptococcal meningoencephalitis
(CM) recommend amphotericin B combined with flucytosine (5-FC) for≥2 weeks as the initial induction treatment
of choice. However, access to flucytosine in Africa and Asia, where disease burden is greatest, is inadequate at
present. While research into identifying effective and well-tolerated antifungal combinations that do not
contain flucytosine continues, an ever-increasing body of evidence from in vitro, in vivo and clinical studies
points to the benefits of flucytosine in the treatment of CM in both intravenous combinations with amphotericin
B and oral combinations with high-dose fluconazole. This article provides an up-to-date review of this evidence,
and the current issues and challenges regarding increasing access to this key component of combination antifun-
gal therapy for cryptococcosis.
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Introduction
History
Flucytosine was first synthesized in 1957 as a potential anti-
tumour agent.1,2 In 1963, murine studies demonstrated that flu-
cytosine was effective against Candida albicans and Cryptococcus
neoformans.3 Flucytosine was first used to treat human candidosis
and cryptococcosis in 1968, and remains one of the oldest antifun-
gal agents still in use.4 – 6 Flucytosine has some activity against
dematiaceous fungi, including those causing chromomycosis,7
and against certain protozoa.8
Structure and mechanism of action
Flucytosine is a synthetic fluorinated analogue of cytosine.1 Flucy-
tosine’s antifungal activity derives from the rapid conversion of flu-
cytosine into 5-fluorouracil (5-FU) within the cytosol of susceptible
fungal cells.9 – 11 Flucytosine itself has no antifungal activity. The
enzyme cytosine permease facilitates uptake of flucytosine into
fungal cells. Cytosine deaminase then rapidly deaminates flucyto-
sine to 5-FU.12 5-FU is a potent antimetabolite that causes RNA
miscoding and inhibits DNA synthesis through two separate
mechanisms (Figure 1).12,13 Whether these two pathways are
linked or independent, what their relative importance for the
total antifungal effect of flucytosine is and what controls the intra-
cellular fate of 5-FU remains unclear.5
Human cells do not possess the enzyme cytosine deaminase,
unlike prokaryotic and fungal cells, and therefore cannot convert
flucytosine into 5-FU.14 – 17 Flucytosine thus appeared to be an
ideal drug, disturbing nucleic acid function exclusively in fungal
cells. However, when flucytosine serum concentrations exceed
100 mg/L, patients experience symptoms of haematological
and gastrointestinal toxicity characteristic of 5-FU chemother-
apy.14,15,18 – 20 Furthermore, 5-FU catabolites have been detected
in the urine and sera of patients at levels comparable to those
found during 5-FU chemotherapy.16,21 Subsequently, in vitro
studies have demonstrated that human intestinal microflora are
capable of converting flucytosine into 5-FU, thus causing the
bone marrow depression, hepatotoxicity, and gastrointestinal dis-
turbance associated with flucytosine chemotherapy.14,22,23 In a
recent Thai study comparing oral and intravenous formulations
of flucytosine for the treatment of HIV-associated cryptococcosis,
despite much lower concentrations of flucytosine detectable with
oral flucytosine, 5-FU was detected in the serum of three patients
on oral flucytosine versus one on intravenous flucytosine.17
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Pharmacokinetics and pharmacodynamics
The absorption of flucytosine is rapid in normal individuals, with
bioavailability reported as 76%–89% after oral administration.24
However, the aforementioned Thai study indicated that the bioavail-
ability of flucytosine, in common with a number of other drugs,25
may be reduced in late-stage HIV-infected patients.17 Indeed, the
ratio of the AUC for oral and intravenous formulations suggested
an oral bioavailability of only 45%.17
Flucytosine is a small, highly water soluble molecule that
achieves good levels in tissue, cerebrospinal and vitreous fluids,
and urine.9,11,26Only 2.9%–4% of the drug is protein bound. Elim-
ination of flucytosine is principally through the kidneys, flucyto-
sine’s plasma clearance being closely related to creatinine
clearance.24,26 In patients with normal renal function, peak con-
centrations of flucytosine occur within 1–2 h of drug administra-
tion,12,24 and the half-life is 3–4 h.24,26 In patients with severe
renal insufficiency, the half-life can increase up to 85 h,24,26 and
the dosage of flucytosine must therefore be carefully adjusted
in patients with renal impairment (Table 1).
Data from in vitro, animal model and some clinical studies
suggests that flucytosine displays concentration-independent,
time-dependent pharmacodynamics.17,27 – 29
In vitro studies
Standardized methods for testing flucytosine susceptibility include
modifications of the CLSI M27-A protocol for susceptibility testing
of yeasts30 and broth microdilution techniques.31 However, data
regarding appropriate breakpoints for defining flucytosine suscep-
tibility in C. neoformansare limited.31,32 Rex and Pfaller31 have sug-
gested that breakpoints similar to those used for Candida species
may be considered for C. neoformans: C. neoformans isolates
with MICs ≤4 mg/L are fully susceptible, isolates with MICs
between 4 and 16 mg/L have intermediate susceptibility,
whereas isolates with MICs.16 mg/L are presumed to be flucyto-
sine resistant.33
In a multicentre study, the in vitro antifungal susceptibility of
C. neoformans to fluconazole, amphotericin B (AmB) and flucyto-
sine failed to predict early clinical outcome in cryptococcosis
patients.34 Different techniques used to determine antifungal sus-
ceptibility include the CLSI method, Etest and broth microdilution in
yeast nitrogen base (YNB) medium.34 A lack of correlation between
in vitro antifungal susceptibility tests and early patient clinical
outcome may be explained by the small number of high MIC
isolates.31,34
Resistance
The estimated prevalence of primary flucytosine-resistant C. neo-
formans is 1%–2%, although incidences of up to 7% have been
reported.35 – 42 In vitro resistance to commonly used antifungal
agents, including flucytosine, has not increased in the UK or the
USA.39,40,43In theUSA, therate ofC.neoformans resistanceto flucyto-
sine ranged from 1.6% in 1992–1994 isolates to 2.2% in 1996–1998
isolates.39 Published data regarding antifungal resistance are limited
in geographical scope and only cover short time spans.
Pfaller et al.40 addressed this limitation in the data by con-
ducting a multicentre antifungal susceptibility study of 1811
FUMP
FdUMP
cytosine
Cell
membrane
permease
5 - FC 5 - FU5 – FC
deaminase
cytosine
FUDP FUTP Incorporationinto RNA
Inhibition
of protein
synthesis
Inhibition of
Thymidylate
synthetase
Inhibition of
DNA synthesis
Figure 1. Intracellular pathway and mode of action of 5-fluorouracil (5-FU). Adapted with permission from Vermes et al.6 5-FU is converted into
5-fluorouridine triphosphate (FUTP). FUTP alters the aminoacylation of tRNA through its incorporation into fungal RNA in place of uridylic acid, causing
RNA miscoding and disturbed synthesis of proteins and carbohydrates. In addition, 5-FU is metabolized to 5-fluorodeoxyuridine monophosphate
(FdUMP). FdUMP is a potent inhibitor of thymidylate synthetase, a key enzyme in the biosynthesis of DNA.
Table 1. Flucytosine renal adjustment table
Creatinine clearance (mL/min)
.40 20–40 10–20 ,10
25 mg/kg
po q6h
25 mg/kg
po q12h
25 mg/kg
po q24h
12.5 mg/kg
po.q24h
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C. neoformans isolates obtained from 100 medical centres in five
geographic regions (Africa, Europe, Latin America, North America
and the Pacific region) over 15 years. Isolates were submitted to
a central reference laboratory and tested using the CLSI (formerly
NCCLS) broth dilution method.40 High-level resistance to flucyto-
sine (MIC ≥32 mg/L) remained essentially unchanged at 1%–2%
over the entire study period,40 consistent with results from
smaller studies from Spain, Egypt and South America.41,42,44
However, interestingly, full susceptibility to flucytosine (MIC
≤4 mg/L) ranged from 35% in North America to 68% in Latin
America.40 North American isolates were considerably less suscep-
tible to both flucytosine and fluconazole compared with other geo-
graphical regions,40 although susceptibilities in North America
isolates increased over time (for flucytosine, from 34% in 1990–
1994 to 66% in 2000–2004).40 The reason for this geographical
and temporal difference in full flucytosine and fluconazole suscep-
tibility remains unclear. It is possible that some isolates were
included from relapse cases and that the improvement in suscep-
tibility mayhave reflected a decrease in such cases and overall drug
pressure of flucytosine and fluconazole with introduction of anti-
retroviral therapy.40
Two potential mechanisms can cause flucytosine resistance: (i)
mutations leading to deficiencies in the enzymes required for cel-
lular uptake or metabolism of flucytosine (i.e. cytosine permease
and deaminase)6,20,45 and (ii) increased synthesis of pyrimidines
that compete with the fluorinated antimetabolites of flucyto-
sine.6,20
Secondary resistance precludes the use of flucytosine as a
single agent.45,46 In vitro studies of flucytosine and other antifun-
gals including AmB suggest the ability to overcome flucytosine re-
sistance may depend on the mechanism of resistance.35,45
If resistance is due to a defective cytosine permease, it may be
overcome bya drug such as AmB that facilitates flucytosine cellular
uptake.35
Indeed, it has been shown that synergy in vitro between AmB
and flucytosine can occur even where there is evidence of resist-
ance to flucytosine.35,47
Experimental cryptococcosis
Flucytosine, alone and in combination, has been studied in murine
and corticosteroid-treated rabbit models of cryptococcosis. In
murine models, AmB plus flucytosine demonstrates additive or
synergistic interactions.48 – 51 The combination of AmB (0.5 mg/
kg/day) and flucytosine (250 mg/kg/day) was significantly more
effective than either AmB or flucytosine monotherapy for reducing
fungal burden in brain and spleen for both flucytosine-susceptible
and flucytosine-resistant isolates in a murine model of dissemi-
nated cryptococcosis.48 Combination therapy with a reduced
dosage of flucytosine at 100 mg/kg/day and AmB at 0.5 mg/kg/
day was still superior to monotherapy for reducing the fungal
burden in the brain, but not the lungs or spleen, for the
flucytosine-resistant isolate.48
In contrast to AmB/flucytosine, a beneficial interaction
between azoles and flucytosine in animal models is less evident.
While the combination of fluconazole and flucytosine appears
beneficial overall in murine models of cryptococcosis,52 – 55 one
study of a rabbit model of meningeal cryptococcosis showed
evidence of a dose–response with fluconazole, but no in vivo
benefit, in terms of reduced cryptococcal cfu counts in the CSF
with the addition of flucytosine to low-dose fluconazole.56 It is
worth noting however, as discussed below, that this flucytosine–
fluconazole interaction, and the nature of drug interactions in
general, may depend critically on the concentration of the compo-
nent drugs used. Earlier studies of combinations of flucytosine with
itraconazole and ketoconazole have also demonstrated indifferent
interactions.49,50
Finally, combinations of all three available agents have been
studied: a study in mice evaluated the antifungal efficacy of AmB
colloidal dispersion (ABCD) combined with flucytosine with or
without fluconazole,52 using regression methods for estimating
and visualizing the dose–response surfaces for survival, weight
loss and brain cfu counts. The combination of ABCD and flucytosine
achieved a 100% survival rate, however, the addition of flucon-
azole was required to prevent weight loss (P,0.001) and to
achieve maximal antifungal effect (P,0.001).52 There was a
strong association between the numbers of cfu recovered per
gram of brain tissue and the dosages of both ABCD and fluconazole
(P,0.001). A moderate association (P,0.01) was seen with the
dosage of flucytosine. Consistent with concentration-independent
activity for flucytosine, maximal fungicidal effect was seen with
high ABCD (5.0–7.5 mg/kg) and fluconazole (≥30 mg/kg/day)
doses but a moderate flucytosine dose (20–60 mg/kg/day).52
Cryptococcosis in clinical studies
Flucytosine monotherapy
Rapid onset of resistance precludes the use of flucytosine mono-
therapy. Hospenthal and Bennet57 described the treatment of 27
HIV-negative patients with disseminated cryptococcal disease
given flucytosine monotherapy when the drug first became avail-
able. Twenty-three patients received either 4 g or 6 g flucytosine
daily, with four patients receiving 7–10 g flucytosine daily. The
initial dosing selection (4 g/day) was based on the historically
approved dose. One-third of patients achieved long-term cure
with flucytosine monotherapy. However, secondary flucytosine re-
sistance occurred in isolates from 50% patients who did not
respond to therapy or relapsed. Flucytosine was nonetheless well
tolerated, even at high doses and for prolonged treatment
courses, with only infrequent and mild toxicity reported.57
Flucytosine and amphotericin B therapy (Table 2)
Clinical trials prior to the HIV epidemic support the use of flucyto-
sine in combination with AmB. In a randomized trial published in
1979, 66 HIV-negative patients were randomized to either
low-dose AmB (0.4 mg/kg/day) for 10 weeks or AmB (0.3 mg/kg/
day) plus flucytosine (150 mg/kg/day) for 6 weeks. In the subset
of 50 patients considered to be adherent, combination therapy
cured or improved 67% of patients compared with 41% of AmB
monotherapy patients, although this result was not statistically
significant.58 Fewer treatment failures or relapses (3 versus 11),
more rapid CSF sterilization (P,0.001) (P¼0.05 if non-adherent
patients were included in this analysis) and less nephrotoxicity
(P,0.05) were noted in the combination arm.58 However, unsur-
prisingly, given the small patient numbers, no mortality difference
was detected.58 Adverse reactions to flucytosine occurred in 11
of 34 patients, but none was considered life threatening.58
Review
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Table 2. Table of key AmB+flucytosine-containing antifungal therapy randomized controlled trials
Study Year
No. of
patients Treatment arms
Treatment
duration
Median time to CSF
sterilization (days)
Deaths at
10 weeks (%) Role of 5FC/AmB combination therapy
Bennett58 (HIV
negative
patients)
1979 51 AmB 0.4 mg/kg 10/52 no difference
in treatment
arms
less nephrotoxicity (P,0.05) and fewer
treatment failures/relapses (3 versus 11)
AmB 0.3 mg/kg+5-FC 150 mg/kg 6/52 more rapid CSF
sterilization
(P,0.001)
Larsen89 1990 20 AmB 0.7 mg/kg+5-FC 150 mg/kg 10/52 16 0 (0/6) superior mycologic and clinical efficacy
FLU 400 mg 10/52 41 (P¼0.02) 28.5 (4/14)
van der Horst60 1997 306 Step 1a: AmB 0.7 mg/kg 2/52 ≤14, 51% versus
60%; P¼0.06
9.4 not receiving 5-FC during initial 2/52¼ factor
associated with CM relapse (RR 5.88,
P¼0.004) (Reich et al.78)
Saag61 Step 2a: AMB 0.7 mg/kg+5-FC
100 mg/kg
2/52 addition of 5-FC during initial 2/52 of treatment
independently associated with CSF
sterilization
Brouwer62 2004 64 AmB 0.7 mg/kg 2/52 ,14 22 AmB+5-FC most rapidly fungicidal regimen
AmB 0.7 mg/kg+5-FC
AmB 0.7 mg/kg+FLU 400 mg
AmB 0.7 mg/kg+5-FC+FLU
400 mg
Bicanic63 2008 64 AmB 0.7 mg/kg+5-FC 2/52 not reported 24 superior mycologic efficacy of higher dose AmB
AmB 1 mg/kg+5-FC
Loyse67 2011 80 AmB 0.7–1 mg/kg+5-FC 2/52 not reported 29 no significant difference in EFA between four
treatment arms
AmB 0.7–1 mg/kg+FLU
600 mg twice daily
AmB 0.7–1 mg/kg+FLU
800 mg/day
AmB 0.7–1 mg/kg+VCZ
300 mg twice daily
Day66 2011 298 AmB 1 mg/kg 4/52 not reported mortality benefit with 2/52 AmB+5-FC
compared with AmB monotherapy at 2/52.
Benefit at 6 months of AmB+5-FC versus
AmB+FLU
AmB 1 mg/kg+5-FC 100 mg/kg 2/52
AmB 1 mg/kg+FLU 400 mg
twice daily
5-FC, 5-fluorocytosine; FLU, fluconazole; AmB, amphotericin B; VCZ, voriconazole.
aThese references represent two steps of the same trial.
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A follow-up randomized trial of 91 HIV-negative patients com-
pared 4 versus 6 weeks of AmB (0.3 mg/kg/day) and flucytosine
(150 mg/kg/day). Six weeks was associated with an 85% cure or
improvement rate (16% relapse rate) versus a 75% cure or im-
provement rate (27% relapse) after 4 weeks of treatment.59 Tox-
icity was reported as significant in both groups (44% versus
43%).59 When comparing early flucytosine serum levels of 38
patients who developed flucytosine toxicity with the levels of 47
patients without toxicity, the development of toxic effects corre-
lated significantly with the presence of serum flucytosine concen-
trations ≥100 mg/L for 2 or more weeks (P¼0.005).59 It is
important to emphasize that low-dose AmB in combination with
high-dose flucytosine was used in both these earlystudies, and flu-
conazole was unavailable.
In the era of the HIV epidemic, more recent trials support AmB-
flucytosine combination therapy. In a landmark trial of higher dose
AmB (0.7 mg/kg) and lower dose flucytosine (100 mg/kg), 2 weeks
of AmB monotherapy was compared with 2 weeks of AmB-
flucytosine combination therapy.60 A trend towards increased
CSF sterilization at 2 weeks was noted with combination therapy
(60% versus 51% for AmB alone, P¼0.06),60 and, in a multivariate
model, the addition of flucytosine was independently associated
with 2 week CSF sterilization (OR 1.92, 95% CI 1.15, 3.22,
P¼0.01).60 Not receiving flucytosine during the initial 2 weeks of
induction treatment was the factor most strongly associated
with cryptococcal meningitis (CM) relapse at a time when no
highly active antiretrovirals were available [relative risk (RR) 5.9,
P¼0.004].61
A randomized trial of 64 HIV-infected CM patients confirmed
that AmB (0.7 mg/kg) plus flucytosine (100 mg/kg/day) was the
most rapidly fungicidal regimen when compared with AmB
alone, AmB plus fluconazole (400 mg/day) or even triple therapy
(AmB plus flucytosine plus fluconazole 400 mg/day).62 The trial
used a new endpoint, rate of clearance of infection, or early fungi-
cidal activity (EFA), based on quantitative CSFcultures. EFA has sub-
sequently proved to be a powerful tool to determine the relative
fungicidal activity of novel antifungal regimens, and in a combined
cohort of.500 patients, was independently associated with mor-
talityat 2 and 10 weeks,alongside altered mental status atpresen-
tation and high baseline fungal burden.63 – 65
In an important Phase III study, 298 patients with afirst episode
of CM were randomized to three induction treatment arms:
4 weeks of AmB (1 mg/kg/day) alone, AmB+flucytosine (100 mg/
kg/day) for 2 weeks or AmB+fluconazole (400 mg twice daily) for
2 weeks. For thefirst time,amortality benefitwas seenwiththeadd-
ition of flucytosine compared with AmB monotherapy [hazard ratio
(HR) 0.57, 95% CI 0.30, 1.08, P¼0.08 at 2 weeks; HR 0.61, 95% CI
0.39, 0.97,P¼0.04 at 10 weeks] (Figure 2).66 There was no statistical
difference in terms of mortality between AmB plus flucytosine and
AmB plus fluconazole at the 2 and 10 week primary endpoints,66 al-
though an adjusted analysis at 6 months found higher mortality
with fluconazole (HR 1.81, 95% CI 1.14, 2.88, P¼0.01). The rate of
clearance of infection (log10 cfu/mL/day) was also greater for AmB
plus flucytosine (HR 20.42, 95% CI 20.44, 20.40) compared with
both AmB monotherapy (HR 20.31, 95% CI 20.34, 20.29) and
AmB plus fluconazole (HR 20.32, 95% CI 20.34, 20.29).66 The
study confirms the clinical as well as mycological superiority of
AmB plus flucytosine over AmB alone. Whether AmB plus high-dose
fluconazole is a reasonable alternative to AmB plus flucytosine
remains an open question, and an important one, given the
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Figure 2. Survival curves, by treatment group, for patients with HIV-associated cryptococcal meningitis in Vietnam treated with AmB (1 mg/kg/day)
(Arm I) alone for 4 weeks (continuous line), with 5-FC (100 mg/kg/day) (Arm II) for 2 weeks (black dashed line) or with fluconazole (800 mg/day for
2 weeks) (grey dotted/dashed line), followed by fluconazole in all three arms. HR (95% CI) at 14/7, II versus I: 0.57 (0.30, 1.08), P¼0.08; III versus I:
0.71 (0.45, 1.11), P¼0.13; at 70/7, II versus I: 0.61 (0.39, 0.97), P¼0.04; III versus I:20.78 (0.44, 1.41), P¼0.42. From Day JN, Tran TTH, Wolbers M et al. N
Engl J Med 2013; 368: 1291–302. Copyright Massachusetts Medical Society 2013. Reprinted with permission.66
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current free availability of fluconazole and the difficulties of obtain-
ing flucytosine in Africa. In terms of clearance of infection, a recent
Phase II study found no significant difference in EFA between AmB
plus flucytosine and AmB plus fluconazole at either 800 or
1200 mg/day.67
In a prospective cohort studyof 230 patients (77% HIVpositive),
the Crypto A/D study, 106 (46%) patients received flucytosine as
part of induction therapy for a median of 12.3+4.3 days (for HIV-
positive patients).68,69The lack of flucytosine therapy during the in-
duction treatment was independently associated with mycologic-
al failure at 2 weeks (OR 3.8, 95% CI 1.9, 7.8]).68 Despite more
severe infections in this group, mycological failure at 2 weeks was
significantly less frequentamongpatientstreated with AmB plus flu-
cytosine than any other regimen (mainly AmB or fluconazole mono-
therapy) [20/86 (23%)versus47/100(47%),P,0.001].69 Treatment
failure (death or mycological failure) in patients with meningo-
encephalitis and abnormal neurology was also less frequent with
AmB plus flucytosine than any other regimen [10/40 (25%) versus
26/36 (72%), P,0.001], and prescription of flucytosine for
,14 days was independently associated with treatment failure at
3 months (OR 3.30, 95% CI 1.12, 9.70, P¼0.03).69
Flucytosine andfluconazole combination therapy (Table3)
Clinical studies consistently support the addition of flucytosine to
high-dose (800–1200 mg/day) fluconazole for the treatment of
CM. In a prospective, open-label cohort study, 32 patients with
HIV-associated CM were treated with oral fluconazole (400 mg/
day) and flucytosine (150 mg/kg/day) for a total of 10 weeks.70
Sixty-three per cent of the patients completed 10 weeks of oral
treatment with a negative CSF culture, and the median time to
CSFsterilization was 23 days. However, side effects were significant
enough to lead to flucytosine withdrawal in nine patients (28%).70
This relatively high rate of flucytosine discontinuation is most likely
related to both the high dose and long course of flucytosine used.
Indeed, 95% of patients tolerated flucytosine for at least 2 weeks.70
In a randomized trial in Uganda, a combination of very-low-dose
fluconazole (200 mg/day) and flucytosine (150 mg/kg/day for the
first 2 weeks) was compared with low-dose fluconazole monother-
apy (fluconazole 200 mg/day for 2 months) in 58 patients. The sur-
vival rate with combination treatment, although disappointing, was
significantlyhigher thanwith fluconazolemonotherapy(32%versus
12%, P¼0.02, at 6 months).71
In a Phase II dose escalation study by Larsenetal.,72 89 patients
with a first episode of HIV-associated CM were treated with 800–
2000 mg/day fluconazole administered alone for 10 weeks or in
combination with flucytosine (100 mg/kg/day) for the first
4 weeks. A dose–response effect was seen with increasing flucon-
azole dose, at least up to 1600 mg/day. The addition of flucytosine
to fluconazole improved the overall response rates (P,0.02, log
rank test), especially at the 800 and 1200 mg/day fluconazole
dosages.72 Overall success, defined as being alive with a negative
CSF culture on or before 10 weeks, was 75% for subjects who
received fluconazole and flucytosine in combination.72
Given evidence for the safety and efficacy of higher dose flucon-
azole,72,73 a more recent randomized trial in Malawi of 44 HIV-
seropositive patients compared the EFA of fluconazole 1200 mg/
day versus fluconazole 1200 mg/day plus flucytosine 100 mg/kg/
day.64 The EFA for the combination arm was significantly higher
than for fluconazole alone (20.28+0.17 log cfu/mL/day versus Ta
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0.11+0.09 log cfu/mL/day, P¼0.001). In addition, there were
fewerdeaths in the combination arm that almost reachedstatistic-
al significance at 2 weeks, despite the small size of the study
(Figure 3).64 Combination therapy was well tolerated despite
more episodes of neutropenia (five versus one, grade III and IV
within the first 2 weeks of antifungal therapy), which were rarely
treatment limiting and not associated with increased evidence of
infection.64 While trials can only be compared with caution, the
EFA of this combination of fluconazole with flucytosine
(20.28 log cfu/mL/day) is the closest an oral antifungal regimen
has come to the fungicidal activity of an AmB monotherapy
regimen (20.31 log cfu/mL/day for AmB 0.7 mg/kg alone in Thai-
land).62,64 The large randomized comparative Phase III ACTA
study will assess whether the oral fluconazole+flucytosine com-
bination is as effective as the recommended AmB+flucytosine
or AmB+fluconazole strategy for induction treatment of
HIV-associated CM [ISRCTN: 45035509].
Safety of flucytosine
The most important side effect of flucytosine is bone marrow de-
pression, particularly neutropenia; other side effects include hep-
atotoxicity, diarrhoea and vomiting. Bone marrow depression
and hepatotoxicity are associated with prolonged high serum flu-
cytosine concentrations, generally .100 mg/L, and are thought
to be mediated by 5-FU.6,58 Flucytosine is a category C drug in preg-
nancy and is teratogenic in rat animal models.
Earlier clinical trials, in which flucytosine toxicity was significant,
used high-dose flucytosine (150 mg/kg/day) for prolonged dura-
tions.58,59,70 Reported toxicity has been significantly less in recent
trials using shorter courses of lower dose flucytosine (100 mg/kg/
day).17,60,62,67,74 Milefchik et al.72 reported grade 4 neutropenia in
18% of patients given flucytosine (100 mg/kg/day) for 4 weeks,
without evidence of increased infections. In the van der Horst
MSG/ACTG study there was a 3% rate of drug discontinuation in
the first 2 weeks with 2 weeks flucytosine, equally split between
202 patients receiving and 179 not receiving flucytosine, and
almost all clearly AmB-related, with no discontinuations due to
neutropenia.60 Similarly in Thailand, 2 weeks AmB plus flucytosine
(100 mg/kg/day) was well tolerated: there were no incidences of
grade 4 neutropenia and no drug discontinuations in the 2 weeks
of combination therapy.17,62 Overall, in EFA studies in Africa and
Asia, flucytosine at 100 mg/kg/day for 2 weeks with either AmB
or fluconazole has been associated with grade 4 neutropenia in
8/183 (4.4%) patients.17,62,64,67,74 – 76 It is important to note that
in all these studies with 2 week flucytosine courses, including
that of the MSG/ACTG, full blood counts and renal function tests,
not flucytosine drug levels, were used to monitor therapy. Never-
theless, current US guidelines recommend monitoring serum flu-
cytosine levels in patients receiving flucytosine after 3–5 days of
therapy, aiming for 2 h post-dose serum flucytosine levels of 30–
80 mg/L,77 to avoid toxicity and prevent emergence of resistance.
Where serum flucytosine level monitoring is not available, bone
marrowand renal function should be monitored frequentlyand flu-
cytosine dose adjustment made with the aid of a nomogram
(Table 1).77 Studies in resource-poor settings have demonstrated
that flucytosine may be used safelyand effectively without flucyto-
sine serum level monitoring for up to 2 weeks, as long as haemato-
logical and renal function are monitored closely, flucytosine dosage
adjustments are made as required and AmB nephrotoxicity is mini-
mized through saline and fluid loading.60,62,64,67,74–76 If grade 4
cytopenias occur, flucytosine should be withheld. Of note, in Africa
many patients have relatively low neutrophil counts78 and not infre-
quently in the course of monitoring, counts, being variable, may
cross the grade 3 threshold but recover spontaneously with repeat
testing.
The reason for the reduced side effects seen with flucytosine at
100 mg/kg/day for 2 weeks in studies of HIV-associated crypto-
coccal infection, and why flucytosine drug level monitoring may
not be essential in this particular setting, may be found in a study
of the pharmacokinetics and dynamics of oral versus intravenous
flucytosine.17 The bioavailability of oral flucytosine in HIV-infected
patients with CM was only50%, and flucytosine levels, although
sufficient to remain above the MIC and therefore maintain efficacy,
were well below those usually associated with toxicity.17 Indeed,
5-FU was infrequently detected in serum.
Guidelines
Based on the evidence outlined above, current treatment guide-
lines are consistent in recommending inclusion of flucytosine in
initial combination therapy for CNS and severe non-meningeal
cryptococcal infection. Current Infectious Diseases Society of
America (IDSA) and WHO guidelines for the management of
HIV-associated CM recommend AmB (0.7–1 mg/kg/day) plus flu-
cytosine (100 mg/kg/day) orally in four divided doses for at least
the first 2 weeks as the induction treatment of choice;77,79 and,
while the recommended AmB formulation and duration of induc-
tion varies, inclusion of flucytosine applies across all host groups:
HIV-infected, transplant (lipid formulations of AmB plus flucyto-
sine), non-HIV non-transplant (induction for 4–6 weeks) and chil-
dren. Only in pregnancy should flucytosine use be carefully
weighed as part of a risk–benefit analysis.
In resource-limited settings, without access to or facilities to
safely give AmB, IDSA guidelines suggest fluconazole at at least
1200 mg/day plus flucytosine, if it is available, as one option for
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Figure 3. Survival curves, by treatment group for patients with
HIV-associated cryptococcal meningitis in Malawi treated with
fluconazole 1200 mg/day or fluconazole 1200 mg/day plus flucytosine
100 mg/kg/day for the initial 2 weeks. One patient lost to follow up was
censored. P¼0.05 at 2 weeks and P¼0.25 at 10 weeks by Cox regression.
Reproduced with permission from Day et al.64
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the initial 2 weeks.77 Advice from the WHO also advocates inclu-
sion of flucytosine in both AmB and high-dose fluconazole-based
combinations, with the proviso that fluconazole should be used
as an alternative second drug with AmB in the many settings
where flucytosine is currently not available.79
Implementation of these recommendations for optimal treat-
ment in resource-limited areas in Africa and Asia with the highest
burden of cryptococcal disease is infrequent, however, and will
remain so until and unless access to flucytosine is widened.
Access to flucytosine
In the context of the HIV epidemic, CM is the leading cause of
community-acquired meningitis in sub-Saharan Africa, causing
an estimated 500000 deaths annually in this region.80 CM mortal-
ity rates remain unacceptably high. In Africa, 10 week mortality
ranges from 24% to .60%.73,76,81 – 84 Widening access to
optimal antifungal therapy requires urgent action if this high asso-
ciated mortality is to be reduced to the lower levels reported from
developed country settings (10 week mortality 10%–26%).60,68
Improving access to essential antifungals must be achieved along-
side efforts to treatpatients earlier through improved diagnostics85
and effective management of CM complications such as raised
intracranial pressure.86
Meda Pharma Pharmaceuticals (France) is the manufacturer of
flucytosine. Recently a new equivalent formulation of oral flucyto-
sine produced by Sigmapharm Labs LLC (USA) has been approved
by the FDA. Flucytosine is manufactured bya numberof companies
in China, Taiwan and India, although the bioequivalence of these
alternate sources of flucytosine is currently unknown. However,
flucytosine is currently unavailable and unregistered in most of
Africa and Asia, where the disease burden is greatest, despite flu-
cytosine being a simple nucleotide analogue that has been off
patent for many years.87,88 The registration of flucytosine in
South Africa, where flucytosine was previously marketed by
Roche, lapsed in 1996.87,88 Even where flucytosine is available, it
is often not administered because of overstated fears regarding
toxicity, or because the severity of cryptococcal disease is underes-
timated. Poor demand coupled with a lack of precise disease
burden data in Africa and Asia have contributed to market failure
for flucytosine. Given the current high cost of flucytosine due to a
lack of competition, generic manufacturers targeting low- and
middle-income countries are urgently needed. In addition, given
the current four times daily dosing, a slow release formulation
would be of great benefit, and should remain equally effective
given the concentration-independent pharmacodynamics of flu-
cytosine.
As the evidence for the benefit of flucytosine-containing com-
bination therapy for cryptococcosis continues to mount, improving
access to flucytosine in sub-Saharan Africa and Asia should
become a key achievable component of efforts to reduce the
global mortality burden from HIV-associated cryptococcal infec-
tion. Coordinated efforts from governmental and international sta-
keholders are required to disseminate and implement current
treatment guidelines, encourage generic flucytosine production,
facilitate flucytosine registration, and widen access to this key
component of combination antifungal therapy for cryptococcal
meningitis.
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